Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
https://www.dailymail.co.uk/news/article-9724745/Matt-Han****-affair-Health-Secretarys-Sky-News-interview-Professor-Neil-Ferguson-resurfaces.html
24 June 2021
DeepVerge plc
("DeepVerge" or the "Company")
Microtox® PD claims world first live data alerts of SARS-Cov-2 in wastewater treatment plants
Modern Water enters Service Agreement with EPS Group for European Microtox®PD[i] installations
DeepVerge (LSE:DVRG.L), today announces the successful completion of Phase 3 field trials in which Microtox® PD achieved real-time detection and transmission of data, specific to SARS-CoV-2, in wastewater treatment plants at multiple sites[ii]. As a result, its Environmental Health Division ("Modern Water") has entered into a master service agreement with EPS Group to install, calibrate, service and maintain Microtox®PD units which, subject to negotiation with undisclosed parties, have the potential to be installed in multiple European countries.
Gerard Brandon, DeepVerge plc CEO commented:
"The successful completion of the Phase 3 field trials clearly demonstrates the capability and value of Microtox® PD to identify dangerous pathogens, including SARS-CoV-2, in real-time. By establishing a permanent anonymised mass surveillance of wastewater, DeepVerge claims a world first real-time defence against this global pandemic. The installation of Microtox® PD wastewater units will enable live data to simultaneously identify the source of COVID-19 cases as well as identify COVID-19 clusters with the ability to indicate the size of each cluster. As the data grows, the central AI system has the potential to predict the trajectory of growth of future clusters of SARS-CoV-2 or any future dangerous pathogen.
"Having achieved this major milestone, we are delighted to enter this agreement with EPS Group who complete the final step of installing, retrofitting and maintaining our Microtox® PD equipment. With this level of established technical engineering support and distribution, DeepVerge can now offer an end-to-end solution for public and private clients across the European wastewater sector. We expect updates from our Joint Venture agreement with China Resources and roll-out in the US to follow early in Q3."
Patrick Buckley, EPS Group Managing Director commented:
"We are very pleased to be part of this innovative partnership with DeepVerge to help combat the pandemic with their unique Microtox® PD technology playing a crucial role in the early detection of COVID-19 hotspots around the world. With 550 personnel, our largest footprint in the water, wastewater pumping and treatment services sector across Europe, EPS Group engineers are ready to make this happen".
Background to field trials:
On the 24 September 2020, the Company announced[iii] completion of the integration of an Affimer/Aptamer-based real-time SARS-CoV-2 detector and alert system into Modern Water's Microtox water contamination system, now called Microtox® PD , for the detection of the coronavirus in wastewater. Microtox® PD successfully completed initial spike pr
Excerpt from today's Express....
Health Secretary Matt Han**** said a new system using daily Covid tests instead of isolation was being trialled by 40,000 people and could soon be rolled out once clinicians have studied the data.
Under the plan to revise quarantine restrictions, the 10-day isolation period could be axed in favour of daily lateral flow tests [fast home kits].
https://www.express.co.uk/news/politics/1452922/coronavirus-news-lockdown-end-july-19
Alastair quote....
“Lateral flow tests have a crucial role to play in helping our society and economy return to normal, and I am confident that the AffiDX® test will now play a significant part in this process.”
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Response to speculation
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, notes speculation regarding the ongoing CE mark submission for its SARS-CoV-2 Antigen Lateral Flow Test to the Medicines and Healthcare products Regulatory Agency ("MHRA") by its partner Mologic Limited ("Mologic").
To date, neither Avacta nor Mologic have received any update from the MHRA. Avacta will update the market when it is in a position to do so.
-Ends -
The National Audit Office (NAO) said last week the cost had risen by more than £100 billion to £372billion since its last report in January this year.
He told the MPs: 'The £372billion is a good, reliable snapshot, based on what we know now. But there are still quite a lot of things that we don’t know.
Tom Scholar told MPs that the current National Audit Office estimate of public expenditure during the pandemic was 'a good, reliable snapshot' but he would expect it to change.
The NAO Covid-19 cost tracker now captures a full year of predicted costs since the pandemic began, with £172 billion already spent
'For example all of those programmes that are demand-driven where the cost will depend on take-up and that in turn will depend on the evolution of the pandemic.
'A very good example would be the cost tot the health service or the cost of the testing programme or the cost of the vaccination programme.
'All of that will depend on the number of tests that will need to be carried out - whether repeat programmes of vaccination turn out to be necessary, we just don’t know yet.
'All of those things will have a big, big impact in the public expenditure figures
https://www.dailymail.co.uk/news/article-9625131/Top-Treasury-official-warns-372billion-Government-spending-Covid-pandemic-RISE.html
https://www.gov.uk/guidance/notify-mhra-about-a-clinical-investigation-for-a-medical-device
CE, CE UKNI and UKCA marks are not issued by the MHRA. They are placed on the product by the manufacturer. Before the product can sold in the UK the manufacturer or their UK Responsible Person (UKRP) must register it with the MHRA.
Tests specifically used for self-testing will need to have been deemed acceptable for CE/CE UKNI/UKCA marking by an Approved or Notified Body or have been granted an Exceptional Use Authorisation by the MHRA. This is indicated by a CE, CE UKNI or UKCA mark and a 4-digit identifier number next to the CE mark symbol on the packaging. Tests which have been granted an Exceptional Use Authorisation.
https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/for-patients-the-public-and-professional-users-a-guide-to-covid-19-tests-and-testing-kits
seems like they are swapping over construction CE markings with post brexit UKCA......busy , busy.....
Not all tests are equal....
https://www.stokesentinel.co.uk/news/stoke-on-trent-news/mum-records-20-positive-lateral-5410336
6 May 2021
Avacta Group plc
("Avacta" or "the Group")
Change of Nominated Adviser
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, announces the appointment of Stifel Nicolaus Europe Limited as Nominated Advisor and Sole Corporate Broker with immediate effect.
Update to disclosures required by Schedule 2(g) of the AIM Rules for Companies
In addition to disclosure of Dr Trevor Nicholls' directorship of Oxloc Limited (as disclosed on 5 August 2013), Oxloc Limited was placed into administration in 2008 and dissolved in 2010.
Oh well....I tried
Change to **********
https://www.**********.co.uk/articles/avacta-paul-hill-discusses-the-clinical-validation-of-their-affidx-lateral-flow-test-glen-goodman-on-crypto-61e9c32/
First 14 mins ...
httpss://www.**********.co.uk/articles/avacta-paul-hill-discusses-the-clinical-validation-of-their-affidx-lateral-flow-test-glen-goodman-on-crypto-61e9c32/
LONDON (Reuters) - Rapid antigen tests on arrival after travel can be just as effective as quarantining to stop imported cases of COVID-19, according to new research which the travel industry hopes will convince Britain to open up its borders this summer.
Britain currently bans all foreign travel, except for work, education or health reasons. However, the government is to review that next month and possibly allow it from May 17.
But rising levels of COVID-19 infections in some European countries and warnings from UK government ministers not to book trips has led to worries that the holiday ban could be extended.
Research commissioned by airlines British Airways-owner IAG, Virgin Atlantic and others found that a single on-arrival antigen test is as effective as a ten-day self-isolation period in reducing imported cases of COVID-19.
Last year, Britain’s 10-day quarantine rules for arrivals from most countries hammered the travel industry, deterring people from taking trips.
After a year of restrictions and minimal revenues airlines are desperate for travel to restart, and when it does they want less risky destinations to be exempt from the requirement to quarantine.
The research, published by consulting firm authors Oxera and Edge Health on Thursday, has been submitted to Britain’s Global Travel Taskforce. The taskforce is reviewing how and when travel should restart and will report on April 12.
“We believe that international travel can safely restart at scale, using a risk-based, phased easing of testing requirements and border restrictions, that follows the scientific evidence,” Virgin Atlantic’s chief executive Shai Weiss said.
For higher-risk countries, a two-test strategy could be a viable option to quarantine, said the report.
https://www.reuters.com/article/worldNews/idUSKBN2BH00D
Really hoping that see this as the final one for Innova
………..….…..........
Status
This tender has been awarded.
The specified contract end date is 31 Mar 2021.
History
16 Mar 2021 - Contract Award Notice
29 Dec 2020 - Tender Notice
Categories
medical consumables
medical equipment